Push-Kurse an | Registrieren | Login
DAX+2,17 % EUR/USD-0,66 % Gold-1,43 % Öl (Brent)+0,79 %

Personalized Medicine Market Worth $149+ Billion by 2020 Covering Companion Diagnostic and Targeted Therapeutics

Nachrichtenquelle: PR Newswire (engl.)
10.02.2016, 03:00  |  951   |   |   

PUNE, India, February 10, 2016 /PRNewswire/ --

The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" research report indicates that the core personalized medicine market will be worth over $149 billion by 2020 growing at a CAGR of 8.74%. This market is made up of companion diagnostics and targeted therapeutics and is dominated by oncology, cardiovascular and infectious disease treatment and diagnostics.

Complete report on personalized medicine, targeted therapeutics and companion diagnostic market spread across 393 pages, analyzing 58 major companies and providing 365 tables & figures is now available at http://www.reportsnreports.com/reports/472795-personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-to-2019-strategic-analysis-of-industry-trends-technologies-participants-and-environment.html.

The report forecasts that the total personalized targeted therapeutic market, for all indications, will grow at a CAGR of 6.47% over the next five years. Strong vertical growth in the companion diagnostic segment however will see a CAGR of 23.71% to 2020, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.

This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analyzed. This study reveals market figures of the overall personalized medicine market and also sub-market figures. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

This new report gives a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The personalized medicine market is presented as follows: By Company (e.g., QIAGEN, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD); By Segment (Targeted therapeutics, Companion Diagnostics); By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy); By Therapy (Cancer, Cardiovascular, Infectious Disease). Order a copy of Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 report @ http://www.reportsnreports.com/purchase.aspx?name=472795.

Companies Mentioned: 23andMe, Abbott Laboratories, Abbott Molecular Inc.,  Admera Health (GENEWIZ),  Affymetrix, Agendia, Alere, Amgen, Astex Pharmaceuticals, AstraZeneca, Atossa Genetics, Becton Dickenson, bioMerieux, BristolMyersSquibb, Cancer Genetics, Celera (Quest Diagnostics), Celldex Therapeutics, Claritas Genomics, CuraGen, Danaher (Leica Biosystems), deCode Genetics (Amgen), Foundation Medicine, EDP Biotech, Eli Lilly, ELDA BioTech, Eisai, Genelex, GlaxoSmithKline, Human Longevity Inc (Cypher Genomics), HalioDx, Ikonisys, Illumina, InterGenetics, Johnson & Johnson, LabCorp, Life Technologies, Merck, MDxHealth, MolecularMD Corporation, Monogram Biosciences, Myriad, Nodality, Novartis MDx, Orion Genomics, Oxford BioTherapeutics, NanoString Technologies, Pfizer, Qiagen, Roche Molecular Diagnostics, Sanofi, SensiGen, Siemens Healthcare Diagnostics, Takeda, Thermo Fisher Scientific, Transgenomic, Ventana (Roche), Vermillion (Ciphergen) and Vertex Pharmaceuticals.

SWOT, Economic & Regulatory Environment specifics include the key strengths, weaknesses and threats influencing leading player position within the market. The report includes the technologies that drive the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing). The report also includes top fastest growing market segments and emerging opportunities supported with the top pharmaceutical companies within the IPM by market share and revenue. The report provides a comprehensive product portfolios, R&D activity and pipeline therapeutics. M&A activity and future strategies of top personalized medicine pharmacos. Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy). CE-marked Personalized Medicine/Diagnostic Tests and the FDA Advances in Personalized Medicine Regulation.

Explore other new reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml


Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com




Schreibe Deinen Kommentar

 

Disclaimer

Personalized Medicine Market Worth $149+ Billion by 2020 Covering Companion Diagnostic and Targeted Therapeutics

PUNE, India, February 10, 2016 /PRNewswire/ --

The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" research report indicates that the core personalized medicine market will be worth over $149 billion by 2020 growing at a CAGR of 8.74%. This market is made up of companion diagnostics and targeted therapeutics and is dominated by oncology, cardiovascular and infectious disease treatment and diagnostics.

Complete report on personalized medicine, targeted therapeutics and companion diagnostic market spread across 393 pages, analyzing 58 major companies and providing 365 tables & figures is now available at http://www.reportsnreports.com/reports/472795-personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-to-2019-strategic-analysis-of-industry-trends-technologies-participants-and-environment.html.

The report forecasts that the total personalized targeted therapeutic market, for all indications, will grow at a CAGR of 6.47% over the next five years. Strong vertical growth in the companion diagnostic segment however will see a CAGR of 23.71% to 2020, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.

This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analyzed. This study reveals market figures of the overall personalized medicine market and also sub-market figures. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

This new report gives a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The personalized medicine market is presented as follows: By Company (e.g., QIAGEN, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD); By Segment (Targeted therapeutics, Companion Diagnostics); By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy); By Therapy (Cancer, Cardiovascular, Infectious Disease). Order a copy of Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 report @ http://www.reportsnreports.com/purchase.aspx?name=472795.

Companies Mentioned: 23andMe, Abbott Laboratories, Abbott Molecular Inc.,  Admera Health (GENEWIZ),  Affymetrix, Agendia, Alere, Amgen, Astex Pharmaceuticals, AstraZeneca, Atossa Genetics, Becton Dickenson, bioMerieux, BristolMyersSquibb, Cancer Genetics, Celera (Quest Diagnostics), Celldex Therapeutics, Claritas Genomics, CuraGen, Danaher (Leica Biosystems), deCode Genetics (Amgen), Foundation Medicine, EDP Biotech, Eli Lilly, ELDA BioTech, Eisai, Genelex, GlaxoSmithKline, Human Longevity Inc (Cypher Genomics), HalioDx, Ikonisys, Illumina, InterGenetics, Johnson & Johnson, LabCorp, Life Technologies, Merck, MDxHealth, MolecularMD Corporation, Monogram Biosciences, Myriad, Nodality, Novartis MDx, Orion Genomics, Oxford BioTherapeutics, NanoString Technologies, Pfizer, Qiagen, Roche Molecular Diagnostics, Sanofi, SensiGen, Siemens Healthcare Diagnostics, Takeda, Thermo Fisher Scientific, Transgenomic, Ventana (Roche), Vermillion (Ciphergen) and Vertex Pharmaceuticals.

SWOT, Economic & Regulatory Environment specifics include the key strengths, weaknesses and threats influencing leading player position within the market. The report includes the technologies that drive the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing). The report also includes top fastest growing market segments and emerging opportunities supported with the top pharmaceutical companies within the IPM by market share and revenue. The report provides a comprehensive product portfolios, R&D activity and pipeline therapeutics. M&A activity and future strategies of top personalized medicine pharmacos. Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy). CE-marked Personalized Medicine/Diagnostic Tests and the FDA Advances in Personalized Medicine Regulation.

Explore other new reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml


Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Die Daten werden nur zum Versenden der Nachricht benutzt und nicht gespeichert.

Abbrechen

Weitere Nachrichten des Autors

Titel
Titel
Titel
Titel
Autor abonnieren

PR Newswire (engl.) jetzt abonnieren

Fügen Sie den Autor Ihren Alerts hinzu und seien Sie immer informiert. Sie können Ihre Alerts bequem in der Alert-Verwaltung bearbeiten. Ebenso können Sie Alerts verknüpfen und individuelle Benachrichtigungen planen.

mehr über Alerts erfahren